RadNet, Inc. (RDNT) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $54.21: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.8/10 and A.R:R 3.7:1 are different metrics that happen to read the same number here.)
RadNet is the largest U.S. operator of freestanding outpatient diagnostic imaging centers by number of locations and revenue, operating 418 centers in nine states (AZ, CA, DE, FL, MD, VA, NJ, TX, NY) as of December 31, 2025, plus hospital/health system joint ventures. Revenue... Read more
Sell if holding. Engine safety override at $54.21: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.8/10 and A.R:R 3.7:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — RadNet, Inc.
Latest news
- Barclays Maintains Overweight on RadNet, Lowers Price Target to $65 — benzinga May 20, 2026 positive
- RadNet Raises FY2026 Sales Guidance from $2.460B-$2.520B to $2.490B-$2.550B vs $2.456B Est — benzinga May 11, 2026 positive
- RadNet Q1 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $575.631M Beat $557.971M Estimate — benzinga May 11, 2026 neutral
- RadNet Forms JV With Saint Alphonsus Health System In Idaho To Operate Three Multimodality Outpatient Imaging Centers — benzinga Apr 30, 2026 positive
- Barclays Maintains Overweight on RadNet, Lowers Price Target to $70 — benzinga Apr 21, 2026 neutral
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -0.7%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $54.21: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.8/10 and A.R:R 3.7:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $50.42. Score 4.8/10, moderate confidence.
Take-profit target: $78.63 (+45.0% upside). Prior stop was $50.42. Stop-loss: $50.42.
Quality below floor (2.1 < 4.0).
RadNet, Inc. trades at a P/E of N/A (forward 56.6). TrendMatrix value score: 6.0/10. Verdict: Sell.
14 analysts cover RDNT with a consensus score of 4.3/5. Average price target: $90.
What does RadNet, Inc. do?RadNet is the largest U.S. operator of freestanding outpatient diagnostic imaging centers by number of locations and...
RadNet is the largest U.S. operator of freestanding outpatient diagnostic imaging centers by number of locations and revenue, operating 418 centers in nine states (AZ, CA, DE, FL, MD, VA, NJ, TX, NY) as of December 31, 2025, plus hospital/health system joint ventures. Revenue comes from multi-modality imaging services billed to a diversified payor mix (commercial, managed care, Medicare, Medicaid) and a growing Digital Health segment (AI-powered radiology software sold to 2,000+ customers including NHS). Revenue is generated by physician referrals to its geographically dense regional networks.